News | February 02, 2026
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Subscribe To Our Newsletter & Stay Updated
